These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 6117849)

  • 1. Central dopamine receptors.
    Flückiger E; Vigouret JM
    Postgrad Med J; 1981; 57 Suppl 1():55-61. PubMed ID: 6117849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol.
    Cubeddu LX; Hoffmann IS; James MK; Niedzwiecki DM
    J Pharmacol Exp Ther; 1983 Sep; 226(3):680-5. PubMed ID: 6887008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the existence of regulatory DA receptors in the substantia nigra.
    Di Chiara G; Mereu GP; Vargiu L; Porceddu ML; Mulas A; Trabucchi M; Spano PF
    Adv Biochem Psychopharmacol; 1977; 16():477-81. PubMed ID: 18896
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacology and biochemistry of dopamine receptors in the central nervous system and peripheral tissue.
    Memo M; Missale C; Carruba MO; Spano PF
    J Neural Transm Suppl; 1986; 22():19-32. PubMed ID: 2431109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Explant cultures of dog substantia nigra and striatum: a model for the study of nigro-striatal dopamine neurons.
    Mytilineou C; Cohen G; Dembiec-Cohen D; Van Woert M; Hwang E
    J Neural Transm Suppl; 1983; 19():37-51. PubMed ID: 6321649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurophysiologic and pharmacologic evidence of autoregulationin the nigrostriatal system].
    Arushanian EB; Tolpyshev BA
    Biull Eksp Biol Med; 1981 Feb; 91(2):133-6. PubMed ID: 7194700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies.
    White FJ; Wang RY
    J Pharmacol Exp Ther; 1984 Nov; 231(2):275-80. PubMed ID: 6491980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of castration on dopamine receptor sensitivity in male young rats: behavioral and neurophysiological studies.
    Asakura W; Ohta H; Matsumoto K; Imamura L; Watanabe H; Matsuda H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1994 Apr; 14(2):77-82. PubMed ID: 8042347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ; György L
    Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some aspects of dopamine in the basal ganglia.
    Carlsson A
    Res Publ Assoc Res Nerv Ment Dis; 1976; 55():181-9. PubMed ID: 12545
    [No Abstract]   [Full Text] [Related]  

  • 14. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
    Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S
    J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
    Melamed E; Hefti F; Wurtman RJ
    Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.
    Miczek KA; Fish EW; De Bold JF; De Almeida RM
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dopaminergic component in the mechanism of action of gamma-aminobutyric acid derivatives and structural analogs].
    Allikmets LKh; Polevoĭ LG; Tsareva TA; Zharkovskiĭ AM
    Farmakol Toksikol; 1979; 42(6):603-6. PubMed ID: 499466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modification of the nigro-striatal system by estrogens and prolactin. Clinical and experimental data].
    Tigano G; Marano P; Patti F; Cammmarata C; De Simone D; Rampello L; Nicoletti F
    Boll Soc Ital Biol Sper; 1982 Aug; 58(16):1054-60. PubMed ID: 7138674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of different doses of apomorphine on the glutamate decarboxylase activity of the substantia nigra and the medial basal hypothalamus].
    Giammona G; Pattí F; Sambataro V; Reggio A; Rampello L; Di Giorgio RM; Maccagnano C; Condorelli DF; Nicoletti F
    Boll Soc Ital Biol Sper; 1981 Oct; 57(20):2074-9. PubMed ID: 7317201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.